Erythropoietin Drugs Market
According to Intent Market Research, the Erythropoietin Drugs Market is expected to grow from USD 6.5 billion in 2023 at a CAGR of 1.9% to touch USD 7.4 billion by 2030. The Erythropoietin Drugs Market is dominated by key players such as Amgen Inc., Roche Holding AG, Johnson & Johnson, Novartis AG, AbbVie Inc., Boehringer Ingelheim, Pfizer Inc., Eli Lilly and Company, Bristol-Myers Squibb, Sandoz International GmbH, Bayer AG, HaploGen, Mylan N.V. (Viatris), Fresenius Medical Care, GSK (GlaxoSmithKline)